Cognition, dopamine and bioactive lipids in schizophrenia

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 1, 2011, Pages 298-330

  Condray, Ruth ^a,b   Yao, Jeffrey K ^a,b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Arachidonic acid; Dopamine; Eicosanoids; Neurocognitive deficits; Phospholipids; Review; Schizophrenia

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; AMPHETAMINE; APOMORPHINE; ARACHIDONIC ACID; CLOZAPINE; DOCOSAHEXAENOIC ACID; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FLUPHENAZINE; HALOPERIDOL; HOMOVANILLIC ACID; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; LEVODOPA; LINOLEIC ACID; LINOLENIC ACID; MEMBRANE PHOSPHOLIPID; NEUROMODULIN; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PLACEBO; POLYUNSATURATED FATTY ACID; URIDINE PHOSPHATE; DOPAMINE; ICOSANOID; PHOSPHOLIPID; UNSATURATED FATTY ACID;

AMNESIA; ARTICLE; BEHAVIOR THERAPY; BRAIN BLOOD FLOW; BRAIN TISSUE; CEREBROSPINAL FLUID; CHRONIC DISEASE; CLINICAL OBSERVATION; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CYTOKINE RELEASE; DECLARATIVE MEMORY; DIET SUPPLEMENTATION; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; EFFECT SIZE; ENVIRONMENTAL FACTOR; EPISODIC MEMORY; EVENT RELATED POTENTIAL; EXECUTIVE FUNCTION; EXPLORATORY BEHAVIOR; FAT INTAKE; FEVER; FOLLOW UP; FOOTSHOCK; FRONTAL CORTEX; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HERITABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INTELLIGENCE TEST; INTERVENTION STUDY; INVOLUNTARY MOVEMENT; LIPID PEROXIDATION; LONG TERM MEMORY; MAINTENANCE DRUG DOSE; MAZE TEST; MENTAL HEALTH; META ANALYSIS; MOTOR PERFORMANCE; NERVE CELL DIFFERENTIATION; NERVE CONDUCTION; NEUROCHEMISTRY; NEUROPSYCHOLOGY; NEUROTRANSMITTER RELEASE; NONHUMAN; NUTRITIONAL DEFICIENCY; OBSERVATIONAL STUDY; OUTPATIENT; OXIDATIVE STRESS; PAIN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PHOSPHOLIPID METABOLISM; PHOSPHOLIPID SYNTHESIS; PREFRONTAL CORTEX; PROSPECTIVE STUDY; PSYCHOSIS; RESPONSE TIME; SCHIZOPHRENIA; SEMANTIC MEMORY; SPATIAL LEARNING; STATE DEPENDENT LEARNING; SUBSTANTIA NIGRA; THROMBOCYTE FUNCTION; TRANSGENIC MOUSE; TREATMENT DURATION; UMBILICAL CORD BLOOD; VERBAL MEMORY; WORKING MEMORY; ANIMAL; BIOLOGICAL MODEL; MEMORY DISORDER; METABOLISM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ANIMALS; COGNITION; DOPAMINE; EICOSANOIDS; FATTY ACIDS, UNSATURATED; HUMANS; MEMORY DISORDERS; MODELS, NEUROLOGICAL; PHOSPHOLIPIDS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 79955971652     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: None     Document Type: Article

References (153)

1. C. J. L. Murray, A. D. Lopez: The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard University Press, Cambridge, MA (1996)
2. B. W. Palmer, R. K. Heaton, J. S. Paulsen, J.Kuck, D. Braff, J. M. Harris, S. Zisook and D. V. Jeste: Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology 11, 437-446 (1997) (Pubitemid 27294667)
3. R. S.E. Keefe, C. E. Eesley and M. P. Poe: Defining a cognitive function decrement in schizophrenia. Biol Psychiatry 57, 688-691 (2005) (Pubitemid 40409709)
4. B. W. Palmer, S. E. Dawes and R. K. Heaton: What do we know about neuropsychological aspects of schizophrenia? Neuropsychol Rev 19, 365-384 (2009)
5. C. R. Bowie, W. W. Leung, A. Reichenberg, M. M. McClure, T. L. Patterson, R. K. Heaton and P. D. Harvey: Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry 63, 505-511 (2008) (Pubitemid 351220787)
6. M. F. Green: What are the functional consequences of neurocognitive deficit in schizophrenia? Am J Psychiatry 153, 321-330 (1996) (Pubitemid 26074706)
7. G. D. Shean: Recent developments in psychosocial treatments for schizophrenic patients. Expert Rev Neurother 7, 817-827 (2007)
8. M. F. Green, R. S. Kern and R. K. Heaton: Longitudinal studies of cognition and functional outcome in schizophrenia: implica tions for MATRICS. Schizophr Res 72, 41-51 (2004) (Pubitemid 39452904)
9. N. Niekawa, Y. Sakuraba, H. Uto, Y. Kumazawa and O. M atsuda: Relationship between financial competence and cognitive function in patient s with schizophrenia. Psychiatry Clin Neurosci 61, 455-461 (2007) (Pubitemid 47414845)
10. J. M. Gold: Cognitive deficits as treatment targets in schizophrenia. Schizophr Res 72, 21-28 (2004) (Pubitemid 39452902)
11. R. W. Buchanan, M. Davis, D. Goff, M. F. Green, R. S. E. Keefe, A. C. Leon, K. H. Nuechterlein, T. Laughren, R. Levin, E. Stover, W. Fenton and S. R. Marder: A summary of the FDA-NIMH-MAT RICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia. Schizophr Bull 31, 5-19 (2005) (Pubitemid 41214353)
12. P. D. Harvey: Pharmacological cognitive enhancement in schizophrenia. Neuropsychology Review 19, 324-335 (2009)
13. M. Fisher, C. Holland, M. M. Merzenich and S. Vinogradov: Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am J Psychiatry 166, 805-811 (2009)
14. E. Tulving: Episodic and semantic memory. In: Organization of memory. Eds: Tulving E, E, Donaldson W, Academic Press, NY (1972)
15. E. K. Warrington: Neuropsychological evidence for multiple memory systems. Ciba Foundation Symposium 69, 153-166 (1979)
16. D. L. Schachter, E. Tulving: What are the memory systems of 1994? In: Memory Systems 1994. Eds: Sc hachter D L, Tulving E, The MIT Press, Cambridge, MA (1994)
17. D. L. Schachter, A. D. Wagner and R. L. Buckner: Memory systems of 1999. In: The Oxford Handbook of Memory. Eds: E. Tulving E, Craik FIM, Oxford University Press, NY (2000)
18. A. Baddeley: Working memory. Oxford University Press, Oxford (1986)
19. A. Baddeley: Working memory: the interface between memory and cognition. In: Memory Systems. Eds: Daniel L. Schachter DL, Tulving E, The MIT Press, Cambridge, MA. (1994)
20. L. R. Squire and S. Zola-Morgan: The medial temporal lobe memory system. Science 253, 1380-1386 (1991) (Pubitemid 21917285)
21. A. Aleman, R. Hijman, E. H. F. de Haan and R. S. Kahn: Memory impairment in schizophrenia: a metaanalysis. Am J Psychiatry 156, 1358-1366 (1999)
22. M. A. Cirillo and L. J. Seidman: Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms. Neuropsychol Rev 13, 43-77 (2003) (Pubitemid 38113372)
23. R. W. Heinrichs and K. K. Zakzanis: Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12, 426-445 (1998) (Pubitemid 28323862)
24. K. H. Nuechterlein, D. M. Barch, J. M. Gold, T. E. Goldberg, M. F. Green and R. K. Heaton: Identification of separable cognitive factors in schizophrenia. Schizophr Res 72, 29-39 (2004) (Pubitemid 39452903)
25. M. F. Green, R. S. Kern, D. L. Braff and J. Mintz: Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff" ? Schizophr Bull 26, 119-136 (2000) (Pubitemid 30317696)
26. M. Cannon, A. Caspi, T. E. Moffitt, H. L. Harrington, A. Taylor, R. M. Murray and R. Poulton: Evidence for earlychildhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry 59, 449-456 (2002) (Pubitemid 34477681)
27. T. J. Crow, D.J. Done and A. Sacker: Childhood precursors of psychosis as clues to its evolutionary origins. Eur Arch Psychiatry Clin Neurosci 245, 61-69 (1995)
28. N. M. Docherty and I. I. Gottesman: A twin study of communication disturbances in schizophrenia. J Nerv Ment Dis 188, 395-401 (2000) (Pubitemid 30464085)
29. N. M. Docherty, S. W. Gordinier, M. J. Hall and L. P. Cutting: Communication disturbances in relatives beyond the age of risk for schizophrenia and their associations with symptoms in patients. Schizophr Bull 25, 851-862 (1999) (Pubitemid 30013565)
30. N. M. Docherty, S. W. Gordinier, M. J. Hall and M. E. Dombrowski: Referential communication disturbances in the speech of nonschizophrenic siblings of schizophrenia patients. J Abnorm Psychol 113, 399-405 (2004) (Pubitemid 39038112)
31. B. A. Maher: A tentative theory of schizophrenic utterance. Prog Exp Pers Res 12, 1-52 (1983)
32. M. J. Minzenberg, B. A. Ober and S. Vinogradov: Semantic priming in schizophrenia: a review and synthesis. J Int Neuropsychol Soc 8, 699-720 (2002)
33. O. J. Doughty and D. J. Done: Is semantic memory impaired in schizophrenia? A systematic review and meta-analysis of 91 studies. Cogn Neuropsychiatry 14, 473-509 (2009)
34. E. Pomarol-Clotet, T. M. S. S. Oh, K. R. Laws and P. J. McKenna: Semantic priming in schizophrenia: systematic review and meta-analysis. The British Journal of Psychiatry 192, 92-97 (2008) (Pubitemid 351269641)
35. M. Kutas and S. A. Hillyard: Reading senseless sentences: brain potentials reflect semantic incongruity. Science 207, 203-205 (1980) (Pubitemid 10141432)
36. M. Kutas and K. D. Federmeier: Electrophysiology reveals semantic memory use in language comprehension. Trends Cognitive Sciences 4, 463-470 (2000)
37. G. R. Kuperberg, D. A. Kreher and T. Ditman: Wh at can event-related potentials tell us about language, and perhaps even thought, in schizophrenia? Int J Psychophysiol (2010)
38. D. H. Mathalon, B. J. Roach and J. M. Ford: Automatic semantic priming abnormalities in schizophrenia. Int J Psychophysiol 75, 157-166 (2010)
39. D. A. Kreher, D. Goff and G. R. Kuperberg: Why all the confusion? Experim ental task explains discrepant semantic priming effects in schizophrenia under "automatic" conditions: evidence from event-related potentials. Schizophr Res 111, 174-181 (2009)
40. R. Condray, S. R. Steinhauer, J. D. Cohen, D. P. van Kammen and A. Kasparek: Modulation of language processing in schizophrenia: effects of context and haloperidol on the event-related potential. Biol Psychiatry 45, 1336-1355 (1999) (Pubitemid 29292511)
41. R. Condray, G. J. Siegle, J. D. Cohen, D. P. van Kammen and S. R. Steinhauer: Automatic activation of the semantic network in schizophrenia: Evidence from eventrelated potentials. Biol Psychiatry 54, 1134-1148 (2003) (Pubitemid 37464859)
42. R. Condray, G. J. Siegle, M. S. Keshavan and S. R. Steinhauer: Effects of word frequency on semantic memory in schizophrenia: electrophysiological evidence for a deficit in linguistic access. Int J Psychophysiology 75, 141- 156 (2010)
43. R. Condray, J. K. Yao, S. R. Steinhauer, D. P. van Kammen, R. D. Reddy and L. A. Morrow: Semantic memory in schizophrenia: association with cell membrane essential fatty acids. Schizophr Res 106, 13-28 (2008)
44. A. J. Saykin, D. L. Shtasel, R. E. Gur, D. B. Kester, L. H. Mozley, P. Stafiniak and R. C. Gur: Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 51, 124-131 (1994)
45. A. J. Saykin, R. C. Gur, R. E. Gur, P. D. Mozley, L. H. Mozley, S. M. Resnick, D. B. Kester and P. Stafiniak: Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry 48, 618-624 (1991)
46. S. V. Faraone, L. J. Seidman, W. S. Kremen, J. R. Pepple, M. J. Lyons and M. T. Tsuang: Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: a diagnostic efficiency analysis. J Abnorm Psychol 104, 286-304 (1995)
47. S. V. Faraone, L. J. Seidman, W. S. Kremen, R. Toomey, J. R. Pepple and M. T. Tsuang: Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: a 4-year follow-up study. J Abnorm Psychol 108, 176-181 (1999) (Pubitemid 29108321)
48. R. E. Gur, M. E. Calkins, R. C. Gur, W. P. Horan, K. H. Nuechterlein, L. J. Seidman and W. S. Stone: The consortium on the genetics of schizophrenia: neurocognitive endophenotypes. Schizophr Bul 33, 49-68 (2007) (Pubitemid 46026259)
49. W. S. Kremen, L. J. Seidman, J. R. Pepple, M. J. Lyons, M. T. Tsuang and S. V. Faraone: Neuropsychological risk indicators for schizophrenia: a review of family studies. Schizophr Bull 20, 103-119 (1994) (Pubitemid 24071096)
50. W. S. Kremen, S. V. Faraone, L. J. Seidman, J. R. Pepple and M. T. Tsuang: Neuropsychological risk indicators for schizophrenia: a preliminary study of female relatives of schizophrenic and bipolar probands. Psychiatry Res 79, 227-240 (1998) (Pubitemid 28346471)
51. B. E. Snitz, A. W. MacDonald III and C. S. Carter: Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull 32, 179-194 (2006) (Pubitemid 43063833)
52. J. L. Thompson, J. R. Watson, S.t R. Steinhauer, G. Goldstein and M. F. Pogue -Geile: Indicators of genetic liability to schizophrenia: a sibling study of neuropsychological performance. Schizophr Bull 31, 85-96 (2005) (Pubitemid 41214359)
53. T. D. Cannon, M. O. Huttunen, J. Lonnqvist, A. Tuulio-Henriksson, T. Pirkola, D. Glahn, J. Finkelstein, M. Hietanen, J. Kaprio and M. Koskenvuo: The inheritance of neuropsychological dysfunction in twins discordant for schizophrenia. Am J Hum Genet 67, 369-382 (2000) (Pubitemid 30616742)
54. T. Toulopoulou, M. Picchioni, F. Rijsdijk, M. Hua-Hall, U. Ettinger, P. Sham and R. Murray: Substantial genetic overlap between neurocognition and schizophrenia: genetic modeling in twin samples. Arch Gen Psychiatry 64, 1348-1355 (2007) (Pubitemid 350223552)
55. T. A. Greenwood, D. L. Braff, G. A. Light, K. S. Cadenhead, M. E. Calkins, D. J. Dobie, R. Freedman, M. F. Green, R. E. Gur, R. C. G ur, J. Mintz, K. H. Nuechterlein, A. Olincy, A. D. Radant, L. J. Seidman, L. J. Siever, J. M. Silverman, W. S. Stone, N. R. Swerdlow, D. W. Tsuang, M. T. Tsuang, B. I. Turetsky and N. J. Schork: Init ial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry 64, 1242-1250 (2007) (Pubitemid 350074822)
56. A. Tuulio-Henriksson , J. Haukka, T. Partonen, T. Varilo, T. Paunio, J. Ekelund, T. D. Cannon, J. M. Meyer and J. Lönnqvist: Heritability and number of quantitative trait loci of neurocognitive functions in families with schizophrenia. Am J Med Genet Part B: Neuropsych Genet 114, 483-490 (2002) (Pubitemid 34680572)
57. J. Flint and M. R. Munafo: The endophenotype concept in psychiatric genetics. Psychological Med 37, 163-180 (2007) (Pubitemid 46158160)
58. G. K. Thaker: Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophr Bull 34, 760-773 (2008) (Pubitemid 351957568)
59. O. D. Howes and S. Kapur: The dopamine hypothesis of schizophrenia: Version III - the final common pathway. Schizophr Bull 35, 549-562 (2009)
60. D. C Javitt: Glutamate and schizophrenia: Phencyclidine, N-Methyl-D-Aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78, 69-108 (2007)
61. D.A. Lewis and B. Moghaddam: Cognitive dysfunction in schizophrenia: convergence of γ- aminobutyric acid and glutamate alterations. Arch Neurol 63, 1372-1376 (2006) (Pubitemid 44547546)
62. J. W. Pettegrew, M. S. Keshavan, K. Panchalingam, S. Strychor, D. B. Kaplan, M. G. Tretta and M. Allen: Alterations in brain high-energy phosphate and membrane phospholipid m etabolism in first-episode, drug-naive schizophrenics: a pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Archives of General Psychiatry 48, 563-568 (1991)
63. M. S. Keshavan, A. G. Mallinger, J. W. Pettegrew and C. Dippold: Erythrocyte membrane phospholipids in psychotic patients. Psychiatry Res 49, 89-95 (1993) (Pubitemid 23329249)
64. D. F. Horrobin: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 30, 193-208 (1998) (Pubitemid 28189552)
65. P. D. Skosnik and J. K. Yao: From phospholipid and fatty ac id defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostaglandins Leukot Essent Fatty Acids 69, 367-384 (2003) (Pubitemid 37464046)
66. S. P. Mahadik and J. K. Yao: Phospholipids in schizophrenia. In: Textbook of Schizophrenia. Eds: Lieberman JA, Stroup TS, Perkins DO, Stroup TS, Perkins DO, The American Psychiatric Publishing, Inc., Washington, DC, (2006)
67. S. Chalon: Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids 75, 259-269 (2006) (Pubitemid 44442912)
68. T. M. du Bois, C. Deng and X-F. Huang: Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 29, 878-888 (2005) (Pubitemid 41080107)
69. K. Ohara: The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31, 469-474 (2007) (Pubitemid 46209444)
70. L. Zimmer, S. Delpal, D. Guilloteau, J, Aïoun, G. Durand and S. Chalon: Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neurosci Letters 284, 25-28 (2000) (Pubitemid 30193190)
71. I. Fedorova, N. Hussein, M. H. Baumann, C. D. Martino and N. Salem Jr: An n-3 fatty acid deficiency impairs rat spatial learning in the Barnes Maze. Behavioral Neurosci 123, 196-205 (2009)
72. A. K. Bhattacharjee, L. Chang, H-J Lee, R. P. Bazinet, R. Seemann and S. I. Rapoport: D2 but not D1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats. Psychopharmacology 180, 735-742 (2005) (Pubitemid 41317869)
73. J. D. Cohen and D. Servan-Schreiber: Context, cortex, and dopamine: a connectionist approach to behavior and biology in schizophrenia. Psychological Rev 99, 45-77 (1992)
74. S. Kapur: Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160, 13-23 (2003) (Pubitemid 36042420)
75. D. G. Daniel, D. R. Weinberger, D. W. Jones, J. R. Zigun, R. Coppola, S. Handel, L. B. Bigelow, T. E. Goldberg, K. F. Berman and J. E. Kleinman: The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 11, 1907-1917 (1991)
76. D. M. Barch and C. S. Carter: Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res 77, 43-58 (2005) (Pubitemid 40957060)
77. U. Kischka, TH. Kammer, S. Maier, M. Weisbrod, M. Thimm and M. Spitzer: Dopaminergic modulation of semantic network activation. Neuropsychologia 34, 1107-1113 (1996) (Pubitemid 26345288)
78. S. Knecht, C. Breitenstein, S. Bushuven, S. Wailke, S. Kamping, A. Flöel, P. Zwitserlood and E. B. Ringelstein: Levodopa: faster and better word learning in normal humans. Ann Neurol 56, 20-26 (2004) (Pubitemid 38857356)
79. D. Roesch-Ely, S. Weiland, H. Scheffel, M. Schwaninger, H-P Hundemer, T. Kolter and M. Weisbrod: Dopaminergic modulation of semantic priming in healthy volunteers. Biol Psychiatry 60, 604-611 (2006) (Pubitemid 44402366)
80. A. F. T. Arnsten, J. X. Cai, B. L. Murphy and P. S. Goldman-Rakic: Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology 116, 143-151 (1994) (Pubitemid 24317040)
81. S. A. Castner and P. S. Goldman-Rak ic: Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. J Neurosci 24, 1446-1450 (2004) (Pubitemid 38222996)
82. A. Costa, A. Peppe, G. Dell'Agnello, C. Caltagirone and G. A. Carlesimo: Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 47, 1374-1381 (2009)
83. H. Takahashi, M. Kato, H. Takano, R. Arakawa, M. Okumura, T. Otsuka, F. Kodaka, M. Hayashi, Y. Okubo, H. Ito and T. Suhara: Differential contributions of prefrontal and hippocampal dopamine D1 and D2 receptors in human cognitive functions. J Neurosci 28, 12032-12038 (2008)
84. P. M. Connolly, C. Maxwell, Y. Liang, J. B. Kahn, S. J. Kanes, T. Abel, R. E. Gur, B. I. Turetsky and S. J. Siegel: The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory components. Neurochem Res 29, 1179-1188 (2004) (Pubitemid 39023492)
85. R. S. Ehrlichman, M. J. Gandal, C. R. Maxwell, M. T. Lazarewicz, L. H. Finkel, D. Contreras, B. I. Turetsky and S. J. Siegel: N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. Neuroscience 158, 705-712 (2009)
86. B. I. Turetsky and G. Fein: Alpha2-noradrenergic effects on ERP and behavioral indices of auditory information processing. Psychophysiology 39, 147-157 (2002) (Pubitemid 34263251)
87. A. Abi-Dargham, R. Gil, J. Krystal, R. M. Baldwin, J. P. Seibyl, M. Bowers, C. H. van Dyck, D. S. Charney, R. B. Innis and M. Laruelle: Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155, 761-767 (1998) (Pubitemid 28252654)
88. A. Abi-Dargham, J. Rodenhiser, D. Printz, Y. Zea-Ponce, R. Gil, L. S. Kegeles, R. Weiss, T. B. Cooper, J. Mann, R. L. Van Heertum, J. M. Gorman and M. Laruelle: From the cover: Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. PNAS 97, 8104-8109 (2000) (Pubitemid 30460780)
89. O. D. Howes, A. J. Montgomery, M-C. Asselin, R. M. Murray, I. Valli, P. Tabraham, E. Bramon-Bosch, L. Valmaggia, L. Johns, M. Broome, P. K. McGuire and P. M. Grasby: Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66, 13-20 (2009)
90. L. S. Kegeles, A. Abi-Dargham, W. G. Frankle, R.Gil, T. B. Cooper, M. Slifstein, D-R. Hwang, Y. Huang, S. N. Haber and M. Laruelle: Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67, 231- 239 (2010)
91. C. Kellendonk, E. H. Simpson, H. J. Polan, G. Malleret, S. Vronskaya, V. Winiger, H. Moore and E. R. Kandel: Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 49, 603-615 (2006) (Pubitemid 43221894)
92. M-E. Bach, E. H. Simpson, L. Kahn, J. J. Marshall, E. R. Kandel and C. Kellendonk: Transient and selective overexpression of D2 receptors in the striatum causes persistent deficits in conditional associative learning. PNAS 105, 16027-16032 (2008)
93. J. A. Benjamins, A. K. Hajra and B. W. Agranoff: Lipids. In: Basic neurochemistry, molecular, cellular, and medical aspects (7th Ed). Eds: Siegel GJ, Wayne AR, Brady ST, Price DL, Elsevier, NY (2006)
94. W. S. Fenton, J. Hibbeln and M. Knable: Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 47, 8-21 (2000) (Pubitemid 30016075)
95. I. Fedorova and N. Salem, Jr: Omega-3 fatty acids and rodent behavior. Prostaglandins Leukot Essent Fatty Acids 75, 271-289 (2006) (Pubitemid 44444990)
96. S. M. Innis: Essential fatty acids in growth and development. Prog Lipid Res 30, 39-103 (1991) (Pubitemid 121002990)
97. D. R. Hoffman, J. A. Boettcher and D. A. Diersen-Schade: Toward optimizing vision and cognition in term infants by dietary docosahexaenoic and arachidonic acid supplementation: a review of randomoized controlled tr ials. Prostaglandins Leukot Essent Fatty Acids 81, 151-158 (2009)
98. A. S. Ryan, J. D. Astwood, S. Gautier, C. N. Kuratko, E. B. Nelson and N. Salem, Jr.: Effects of long-chain polyunsaturated fatty acid supplementation on neurodevelopment in childhood: a review of human studies. Prostaglandins Leukot Essent Fatty Acids 82, 305- 314 (2010)
99. K. Simmer, S. Patole and S. C. Ra o: Longchain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database of Systematic Reviews 1. Art.No.: CD000376 (2008)
100. M. P. Freeman, J. R. Hibbeln, K. L. Wisner, J. M. Davi s, D. Mischoulon, M. Peet, P. E. Keck, L. B. Marangell, A. J. Richardson, J. Lake and A. L. Stoll: Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 67, 1954-1967 (2006) (Pubitemid 46048194)
101. R. K. McNamara and S. E. Carlson: Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot Essent Fatty Acids 75, 329-349 (2006) (Pubitemid 44442917)
102. M. Peet: Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia. Isr J Psychiatry Relat Sci 45, 19-25 (2008)
103. A. J. Richardson: Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. International review of psychiatry 18, 155-172 (2006) (Pubitemid 43791677)
104. S. Holguin, Y. Huang, J. Liu and R. Wurtman: Chronic administration of D HA and UMP improves the impaired memory of environmentally impoverished rats. Behav Brain Res 191, 11-16 (2008)
105. A. L. Petursdottir, S. A. Farr, J. E. Morley, W. A. Banks and G. V. Skulad ottir: Effect of dietary n-3 polyunsaturated fatty acids on brain lipid fatty acid composition, learning ability, and memory of senescenceaccelerated mouse. J Gerontol A Biol Sci Med Sci 63A, 1153-1160 (2008) (Pubitemid 352772035)
106. A. Eilander, D.C. Hundscheid, S.J. Osendarp, C. Transler and P.L. Zock: Effects of n-3 long chain polyunsaturated fatty acid supplementation on visual and cognitive development throughout childhood: A review of human studies. Prostag landins Leukot Essent Fatty Acids 76, 189-203 (2007) (Pubitemid 46613865)
107. J. P. Schuchardt, M. Huss, M. Stauss-Grabo and A. Hahn: Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children. Eur J Pediatr 169, 149- 164 (2010)
108. J. Colombo , K.N. Kannass , D. J. Shaddy , S. Kundurthi , J. M. Maikranz , C. J. Anderson , O. M. Blaga and S. E. Carlson: Maternal DHA and the development of attention in infancy and toddlerhood. Child Dev 75, 1254-1267 (2004) (Pubitemid 39137766)
109. J. A. Dunstan, K. Simmer, G. Dixon and S. L. Prescott: Cognitive assessment of children at age 2 years after maternal fish oil supplementation in pregnancy: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 93, F45-F50 (2008)
110. J. L. Jacobson, S. W. Jacobson, G. Muckle, M. Kaplan-Estrin, P. Ayotte and E. Dewailly: Beneficial effects of a polyunsaturated fatty acid on infant development: evidence from the Inuit of Arctic Quebec. J Pediatrics 152, 356-364 (2008)
111. M. A. Beydoun, J. S. Kaufman, J. A. Satia, W. Rosamond and A. R. Folsom: Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 85, 1103-1111 (2007) (Pubitemid 46557928)
112. C. Dullemeijer, J. Durga, I. A. Brouwer, O. van de Rest, F. J. Kok, R-J. M. Brummer, M. P. J. van Boxtel and P. Verhoef: n-3 Fatty acid proportions in plasma and cognitive performance in older adults. Am J Clin Nutr 86, 1479-1485 (2007) (Pubitemid 350126254)
113. O. van de Rest, J. M. Geleijnse, F. J. Kok, W. A. van Staveren, C. Dullemeijer, M.G.M. OldeRikkert, A. T.F. Beekman and C. P.G.M. de Groot: Effect of fish oil on cognitive performance in older subjects: A randomized, controlled trial. Neurology 71, 430-438 (2008)
114. O. van de Rest, A. Spiro III, E. Krall-Kaye, J. M. Geleijnse, L. C. P. G. M. de Groot and K. L. Tucker: Intakes of (n-3) fatty acids and fatty fish are not associated with cognitive performance and 6-year cognitive change in men participating in the Vetera ns Affairs Normative Aging Study. J Nutr 139, 2329-2336 (2009)
115. G. P. Amminger, M. R. Schäfer, K. Papageorgiou, C. M. Klier, S. M. Cotton, S. M. Harrigan, A. Mackinnon, P. D. McGorry and G. E. Berger: Long-chain ω-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Arch Gen Psychiatry 67, 146- 154 (2010)
116. G. E. Berger, T-M. Proffitt, M. McConchie, H. Yuen, S. J. Wood, G. P. Amminger, W. Brewer and P. D. McGorry: Ethyl-eicosapentaenoic acid in first-episode psychosis: A randomized, placebo-controlled trial. J Clin Psychiatry 68, 1867-1873 (2007)
117. W. S. Fenton, F. Dickerson, J. Boronow, J. R. Hibbeln and M. Knable: A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 158, 2071-2074 (2001) (Pubitemid 33104119)
118. M. Peet and D.F. Horrobin: A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatric Research 36, 7-18 (2002) (Pubitemid 34037843)
119. R. Emsley, C. Myburgh, P. Oosthuizen and S.J. van Rensburg: Randomized, placebo-controlled study of ethyleicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 159, 1596-1598 (2002) (Pubitemid 35006744)
120. L. J. Whalley, I. J. Deary, J. M. Starr, K. W. Wahle, K. A. Rance, V. J. Bourne and H. C. Fox: n-3 fatty acid erythrocyte membrane content, APOE ε4, and cognitive variation: an observational follow-up study in late adulthood. Am J Clin Nutr 87, 449-454 (2008) (Pubitemid 351226084)
121. G. W. Arendash, M.T. Jensen, N. Salem Jr, N. Hussein, J. Cracchiolo, A. Dickson, R. Leighty and H. Potter: A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice. Neuroscience 149, 286-302 (2007) (Pubitemid 47576542)
122. H. O. Bang, J. Dyerberg and H. M. Sinclair: The composition of the Eskimo food in north western Greenland. Am J Clin Nutr 33, 2657-2661 (1980) (Pubitemid 11172006)
123. E. Cyhlarova, J. G. Bell, J. R. Dick, E. E. Mackinlay, J. F. Stein and A. J. Richardson: Membrane fatty acids, reading and spelling in dyslexic and non-dyslexic adults. European Neuropsychopharmacology 17, 116-121 (2007) (Pubitemid 44779188)
124. Y. Ishikura, G. Ikeda, K. Akimoto, M. Hata, A. Kusumoto, A. Kidokoro, M. Kontani, H. Kawashima, Y. Kiso and Y. Koga: Arachidonic acid supplementation decreases P300 latency and increases P300 amplitude of event-related potentials in healthy elderly men. Neuropsychobiology 60, 73-79 (2009)
125. D. F. Horrobin, K. Jenkins, C.N. Bennett and W. W. Christie: Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding. Prostaglandins Leukot Essent Fatty Acids 66, 83-90 (2002) (Pubitemid 34717690)
126. N. G. Bazan: The onset of brain injury and neurodegeneration triggers the synthesis of docosanoid neuroprotective signaling. Cell Mol Neurobiol 26, 901-913 (2006)
127. S. Akhondzadeh, M. Tabatabaee, H. Amini, S. A. A. Abhari, S. H. Abbasi and B. Behnam: Celecoxib as adjunctive t herapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophr Res 90, 179-185 (2007) (Pubitemid 46177578)
128. J. K. Yao: Abnormalities of fatty acid metabolism in red cells, platelets and brain in schizophrenia. In: Phospholipid spectrum disorders in psychiatry and neurology (2nd edition). Eds: Peet M, Glen I and Horrobin DF, Marius Press, Lancashire, UK, (2003)
129. M. Peet: Membrane fatty acid deficit in schizophrenia and mood disorders. In: Fatty acids and oxidative stress in neuropsychiatric disorders. Eds: Reddy R, Yao JK. Nova Science Publishers, Inc., NY (2007)
130. S. M. Conklin, C. Runyan, S. Leonard, R. D. Reddy, M. F. Muldoon and J. K. Yao: Age-related changes of n-3 and n-6 polyunsaturated fatty acids in the anterior cingulate cortex of individuals with major depressive disorder. Prostaglandins Leukot Essent Fatty Acids 82, 111 -119 (2010)
131. D. F. Horrobin: Schizophrenia as a prostaglandin deficiency disease. Lancet 309, 936-937 (1977)
132. W. W Eaton, C. Hayward and R. Ram: Schizophre nia and rheumatoid arthritis: a review. Schizophr Res 6, 181-192 (1992)
133. R. J. Oken and M. Schulzer: At Issue: Schizophrenia and rheumatoid arthritis: the negative association revisited. Schizop hr Bull 25, 625-638 (1999) (Pubitemid 30013548)
134. S. Vinogradov, I. I. Gottesman, H. W. Moises and S. Nicol: Negative association between schizophrenia and rheumatoid arthritis. Schizophr Bull 17, 669-678 (1991)
135. G. C. Davis, M. S. Buchsbaum, D. P. van Kammen and W. E. Bunney Jr: Analgesia to pain stimuli in schizophrenics and its reversal by naltrexone. Psychiatry Res 1, 61-69 (1979) (Pubitemid 10124715)
136. F. Wanibuchi and S. Usuda: Synergistic effects between D-1 and D-2 dopamine antagonists on catalepsy in rats. Psychopharmacology (Berl) 102, 339-342 (1990) (Pubitemid 20335060)
137. N. Ono, T. Abiru, K. Sugiyama and H. Kamiya: Influences of cyclooxygenase inhibitors on the cataleptic behavior induced by haloperidol in mice. Prostaglandins Leukotrienes Essent Fatty Acids 46, 59-63 (1992)
138. R. C. S. Barcelos, D. M. Benvegnú, N. Boufleur, P. Reckziegel, L. G. Müller, C. Pase, T. Emanuelli and M. E. Bürger: Effects of ω-3 essential fatty acids (ω-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter. Neurotox Res 17, 228-237 (2010)
139. J. Drtil: Analgesics-antipyretics and etiology and pathogenesis of psychosis. Activitas Nervosa Superior 13, 237-238 (1971)
140. R. A. Hoppmann, J. G. Peden and S. K. Ober: Central nervous system side effects of nonsteroidal antiinflammatory d rugs: aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med 151, 1309-1313 (1991)
141. N. Sussman and S. Magid: Psychiatric manifestations of nonsteroidal anti-inflammatory drugs. Primary Psychiatry 7, 26-30 (2000) (Pubitemid 33210266)
142. D. L. Braff, R. Freedman, N. J. Schork and I. I. Gottesman: Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull 33, 21-32 (2007) (Pubitemid 46026257)
143. M. S. Keshavan, R. Tandon, N. N. Boutros and H. A. Nasrallah: Schizophrenia, " Just the facts": what we know in 2008 Part 3: neurobiology. Schizophr Res 106, 89-107 (2008)
144. J. K. Yao, D. P. van Kammen and J. A. Welker: Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res 13, 217-226 (1994) (Pubitemid 24302651)
145. S. P. Mahadik and D. R. Evans: Is Schizophrenia a metabolic brain
146. J. K. Yao and D. P. van Kammen: Membrane phospholipids and cytokine interaction in schizophrenia. Int Rev Neurobiology 59, 297-326 (2004) (Pubitemid 39753905)
147. S. Chalon, S. Vancassel, L. Zimmer, D. Guilloteau and G. Durand: Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids 36, 937-944 (2001) (Pubitemid 33065195)
148. S. Delion, S. Chalon, J. Hérault, D. Guilloteau, J-C Besnard and G. Durand: Chronic dietary -linolenic acid deficiency alters dopaminergic and serotoninergic neurotransmission in rats. J Nutr 124, 2466-2476 (1994)
149. S. Delion, S. Chalon, D. Guilloteau, J-C Besnard and G. Durand: α-linolenic acid dietary deficiency alters agerelated changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem 66, 1582-1591 (1996)
150. L. Zimmer, S. Hembert, G. Durand, P. Breton, D. Guilloteau, J. -C. Besnard and S. Chalon: Chronic n-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex: a microdialysis study. Neurosci Letters 240, 177-181(1998) (Pubitemid 28079051)
151. S. Chalon, S. Delion-Vancassel, C. Belzung, D. Guilloteau, A-M. Leguisquet, J-C Besnard and G. Durand: Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr 128, 2512-2519 (1998) (Pubitemid 29013003)
152. K-F. Ng and S. M. Innis: Behavioral responses are altered in piglets with decreased frontal cortex docosahexaenoic acid. J Nutr 133, 3222-3227 (2003) (Pubitemid 37222245)
153. D. P. van Kammen, M. E. Kelley, J. A. Gurklis, M. W. Gilbertson, J. K. Yao, R. Condray and J. L. Peters: Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients. Neuropsychopharmacology 14, 275-283 (1996) (Pubitemid 26120554)